ArticleMovement disorders : official journal of the Movement Disorder Society2026
Elevation of Stearoyl-Coenzyme A Desaturase and Monounsaturated Fatty Acids in Parkinson's Disease Serum.
Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidence indicates that dysregulation of monounsaturated fatty acids (MUFAs), synthesized by the enzyme stearoyl-coenzyme A desaturase (SCD), impacts on α-synuclein pathology in the Parkinson's disease (PD) brain.
objectiveThe objective of this study was to analyze SCD and MUFA-enriched lipids in the periphery of patients with sporadic PD compared with healthy control subjects.
methodsSerum SCD protein was quantified using enzyme-linked immunosorbent assay in patients with PD (n = 40) and control subjects (n = 41). Lipidomic profiling was performed using liquid chromatography-mass spectrometry and LipidSearch software. Statistical analyses included Mann-Whitney U tests and Welch's t tests with false discovery rate (FDR) correction.
resultsSCD levels were higher in PD (mean = 1702 pg/ml) compared with control subjects (1158 pg/ml; P = 2.2 × 10
conclusionsIncreased SCD and MUFA-enriched lipids indicate altered membrane and sphingolipid metabolism in PD, consistent with central disease pathology, that present a potential for novel biomarker development for PD. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.